The total number of records retrieved from this search are 10. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2242	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2243	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2244	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2245	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2246	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2247	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2248	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2249	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2250	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2251	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMCF-10A	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767